ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2213

Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis

Hiroto Yoshida1, Mika Yagoto1, Miho Suzuki1, Keisuke Tanaka1, Isao Matsumoto2, Takayuki Sumida3 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, 3Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: animal models and tumor necrosis factor (TNF), IL-6, osteoporosis, rheumatoid arthritis, WNT Signaling

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1) and sclerostin. However, it is not fully understood how development of arthritis affects DKK-1 and sclerostin production, or if levels of DKK-1 and sclerostin are improved by blockade of interleukin-6 (IL-6) or tumor necrosis factor-α (TNF-α). The purpose of this study was to examine DKK-1 and sclerostin production in inflammatory arthritis and how it is affected by blockade of IL-6 or TNF-α, using a mouse model of collagen-induced arthritis (CIA).

Methods: CIA in DBA/1J mice was triggered by intradermal injection of bovine type II collagen on Days 0 and 21. Mice were injected intraperitoneally with either anti-mouse IL-6 receptor antibody (MR16-1) on Days 0 and 21 or with TNF receptor-Fc (TNFR-Fc) 3 times per week from the first immunization. Serum was sampled on Days 14 (before swelling), 35 (peak of swelling), and 56 (after swelling subsides). Serum Wnt signalling inhibitors (DKK-1 and sclerostin) were measured by ELISA. Hind limb bones (periarticular bone) and the lumbar spine (systemic bone) were excised on Day 56. Bone volume (BV/TV) of the hind limb (cuboid bone) and the lumbar spine (trabecular bone of L6) was analysed by micro-computed tomography (μCT).

Results: In CIA mice, BV/TV of the hind limb and lumbar spine on Day 56 were significantly decreased to 72.6% (p<0.0001) and 62.1% (p<0.0001) of the respective values in non-immunized mice. MR16-1 and TNFR-Fc each significantly suppressed the development of arthritis (p<0.001 and p<0.05) and bone loss in the hind limb (p<0.0001 and p<0.01) compared with untreated CIA mice. On the other hand, bone loss in the lumbar spine was significantly suppressed by only MR16-1 (p<0.0001) and not by TNFR-Fc (p=0.367). On Days 14, 35, and 56, DKK-1 levels were significantly higher in CIA mice than in non-immunized mice (p<0.0001). Sclerostin levels were significantly lower on Days 14 and 35 in CIA mice than in non-immunized mice (p<0.0001). In MR16-1-treated CIA mice, DKK-1 was significantly lower than in untreated CIA mice on Days 35 and 56 (p<0.0001 and p<0.01), and sclerostin was significantly higher on Days 14 and 35 (p<0.0001). In TNFR-Fc-treated CIA mice, on the other hand, although DKK-1 on Day 35 was as significantly decreased as it was in MR16-1-treated mice (p<0.0001), sclerostin levels on Day 35 were similar to those of untreated CIA mice (p=0.988).

Conclusion: The high DKK-1 level in CIA mice was suppressed by blockade of not only TNF-α but also IL-6. This result indicates one mechanism through which blockade of TNF-α and IL-6 suppresses periarticular bone loss. However, DKK-1 might not affect systemic bone loss because TNFR-Fc treatment did not suppress bone loss in the lumbar spine. On the other hand, although sclerostin levels were significantly lower in CIA mice than in non-immunized mice, sclerostin levels were normalized only by blockade of IL-6. Our findings suggested that anti-IL-6 receptor antibody would have a beneficial effect on both periarticular and systemic bone loss by normalizing the Wnt pathway in inflammatory arthritis.


Disclosure: H. Yoshida,
None;

M. Yagoto,
None;

M. Suzuki,
None;

K. Tanaka,
None;

I. Matsumoto,
None;

T. Sumida,
None;

Y. Matsumoto,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-il-6-receptor-antibody-normalizes-both-dkk-1-and-sclerostin-as-wnt-inhibitors-in-a-mouse-model-of-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology